Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker
Authors:
- Yuling WangYWYuling Wang
- Vijaya RamachandranVRVijaya Ramachandran
- Dawen SuiDSDawen Sui
- Kejing XuKXKejing Xu
- Lauren E. HayduLHLauren E. Haydu
- Shenying FangSFShenying Fang
- Jennifer L. McQuadeJMJennifer L. McQuade
- Sarah B. FisherSFSarah B. Fisher
- Anthony LucciALAnthony Lucci
- Emily Z. KeungEKEmily Z. Keung
- Jennifer WargoJWJennifer Wargo
- Jeffrey E. GershenwaldJGJeffrey E. Gershenwald
Open Access
- 21 December 2021
- journal article
- editorial
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (7) , 2046-2049.e3
Abstract
No abstract availableKeywords
Funding Information
- NCI
- UTMDACC
This publication has 17 references indexed in Scilit:
- Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive ProteinJournal of Clinical Oncology, 2016
- Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with IpilimumabOncoImmunology, 2016
- C-Reactive Protein As a Marker of Melanoma ProgressionJournal of Clinical Oncology, 2015
- IL-6-stimulated CD11b+CD14+HLA-DR− myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagusOncotarget, 2014
- Interleukin-6 signaling pathway in targeted therapy for cancerCancer Treatment Reviews, 2012
- Interleukin-6 and melanomaMelanoma Research, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective studyMelanoma Research, 2005
- Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy?Melanoma Research, 1999
- Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden.1996